🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Nivolumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  2. OKI-219

    OnKure Therapeutics

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  3. OMP-21M18

    Mereo BioPharma Group plc

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  4. OMP-305B83

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule terminated

    1 trial

  5. OMP-305B83

    Mereo BioPharma Group plc

    Cancer Ovaries

    phase 1 small molecule completed

    1 trial

  6. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  7. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  8. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  9. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  10. ONO-4578

    Ono Pharmaceutical Co.,

    Metastatic Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  11. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  12. ORIC-944

    Topiloric/Uriadec

    Metastatic Prostate Cancer

    phase 1 small molecule active

    1 trial

  13. Olaparib tablets, 150 mg

    Sandoz Pty Ltd

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  14. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  15. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  16. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  17. PAN-301-1

    Sensei Biotherapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

  18. PARP inhibitor BMN-673

    BioMarin Pharmaceutical Australia Pty Ltd

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  19. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

  20. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  21. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  22. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  23. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  24. PRT3645

    Prelude Therapeutics Inc

    Breast Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources